

Michael Melnick, PhD

One Embarcadero Center, Suite 3250
San Francisco CA 94111
Office 415-901-0622
michael@cmea.com

CMEA Capital San Francisco, CA
Principal 2007-present

- Member of the Energy and Materials team, focused on biofuels and renewable chemicals opportunities. Acting CEO of algae startup Biolight Harvesting, Inc., and board observer of renewable chemical company Draths Corporation.

Assay Designs, Inc. Ann Arbor, MI
Chief Commercial Officer 2006-2007

- Responsible for the company's antibody business, including development and production
- Responsible for Sales, Marketing, and Business and Corporate Development
- Leader of the company's strategic and operational planning process

Cell Signaling Technology, Inc. Danvers, MA
Vice President, Business and Corporate Development 2003-2006
Co-founder, Director of Business and Corporate Development 1999-2003

- Organized the business side of this spin-off from New England Biolabs
- Grew the company to 200 employees and \$50 million in sales.
- Led strategic and operational planning
- Led Sales, Marketing and Business Development

New England Biolabs, Inc. Ipswich, MA
Staff Scientist 1998-1999
Research Fellow (laboratory of Michael Comb) 1995-1998

Education

Harvard University Cambridge, MA
Ph.D. in Genetics (laboratory of Norbert Perrimon) 1995

- Drosophila genetics to elucidate human protein kinase oncogene pathways

Stanford University Stanford, CA
M.S. in Biological Sciences (laboratory of Dow Woodward) 1986
B.S. with honors in Biological Sciences 1986

Michael Melnick: Selected Publications

Aruffo A, Stamenkovic I, **Melnick M**, Underhill C, Seed B. 1990. CD44 is the principal cell surface receptor for hyaluronate. *Cell* 61, 1303-1313.

Aruffo A, **Melnick MB**, Linsley P, Seed B. 1991. The lymphocyte glycoprotein CD6 contains a repeated domain structure characteristic of a new family of cell surface and secreted proteins. *J. Exp. Med.* 174, 949-952.

Melnick MB, Perkins LA, Lee M, Ambrosio L, Perrimon N. 1993. Developmental and molecular characterization of mutations in the *Drosophila*-raf serine/threonine protein kinase. *Development* 118,127-138.

Melnick MB, Noll E, Perrimon N. 1993. The *Drosophila stubarista* phenotype is associated with a dosage effect of the putative ribosomal protein D-p40 on spineless. *Genetics* 135, 553-564.

Lu XY, **Melnick MB**, Hsu R, Perrimon N. 1994. Genetic and molecular analyses of mutations involved in *Drosophila*-Raf signal transduction. *EMBO J.* 13, 2592-2599.

Hou XS, Chou TB, **Melnick MB**, Perrimon N. 1995. Torso activates Raf in a Ras-independent pathway. *Cell* 81, 63-71.

Hou S, **Melnick MB**, Perrimon N. 1996. Marelle acts downstream of the *Drosophila* Hop/JAK kinase and encodes a protein similar to the mammalian STATs. *Cell* 84, 411-419.

Goode, S, **Melnick MB**, Chou TB, Perrimon N. 1996. The neurogenic genes egghead and brainiac define a novel signaling pathway essential for epithelial morphogenesis during *Drosophila* oogenesis. *Development* 122, 3863-3879.

Eberl DF, Lorenz LJ, **Melnick MB**, Sood V, Lasko P, Perrimon N. 1997. A new enhancer of position-effect variegation in *Drosophila melanogaster* encodes a putative RNA helicase that binds chromosomes and is regulated by the cell cycle. *Genetics* 146, 951-963.

Li W, **Melnick M**, Perrimon N. 1998. Dual function of Ras in Raf activation. *Development* 125, 4999-5008.

Carroll RS, Zhang J, Bello L, **Melnick MB**, Maruyama T, Black PM. 1999. KDR activation in astrocytic neoplasms. *Cancer* 86(7), 1335-1341.

Lorenzen JA, Baker SE, Denhez F, **Melnick MB**, Brower DL, Perkins LA. 2001. Nuclear import of activated D-ERK by DIM-7, an importin family member encoded by the gene moleskin. *Development* 128, 1403-1414.

Davids MS, Crawford E, Weremowicz S, Morton CC, Copeland NG, Gilbert DJ, Jenkins NA, Phelan MC, Comb MJ, **Melnick MB**. 2001. STK25 is a candidate gene for pseudopseudohypoparathyroidism. *Genomics* 77(1-2), 2-4.

Chen HW, Marinissen MJ, Oh SW, Chen X, **Melnick M**, Perrimon N, Gutkind JS, Hou SX. 2002. CKA, a novel multidomain protein, regulates the Jun N-terminal kinase signal transduction pathway in *Drosophila*. *Mol. Cell. Biol.* 22(6), 1792-1803.

Wetzel R, Goss VL, Norris B, Popova L, **Melnick M**, Smith BL. 2005. Evaluation of CML model cell lines and imatinib mesylate response: determinants of signaling profiles. *J. Immunol. Methods* 305(1), 59-66.

Cho J, **Melnick M**, Solidakis GP, Tschlis PN. 2005. Tpl2 (tumor progression locus 2) phosphorylation at Thr290 is induced by lipopolysaccharide via an I κ B Kinase Beta-dependent pathway and is required for Tpl2 activation by external signals. *J. Biol. Chem.* 280(21), 20442-20448.